<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704416</url>
  </required_header>
  <id_info>
    <org_study_id>PacificRERI</org_study_id>
    <nct_id>NCT02704416</nct_id>
  </id_info>
  <brief_title>Ablation in Brugada Syndrome for the Prevention of VF</brief_title>
  <acronym>BRAVE</acronym>
  <official_title>Ablation in Brugada Syndrome for Prevention of VF - A Randomized, Multi-center Study of Epicardial Ablation in Brugada Syndrome Patients to Prevent Arrhythmia Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacific Rim Electrophysiology Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pacific Rim Electrophysiology Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to develop evidence based curative treatment with optimal net benefit for
      patients with Brugada syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to develop evidence based curative treatment with optimal net benefit for
      patients with Brugada syndrome. Since a recent non-randomized pilot study and scarce case
      reports documented potential clinical benefit of epicardial ablation of fragmented
      electrograms in the region of the right ventricular outflow tract, patients in this trial
      will be randomized to continued implanted cardioverter defibrillator therapy (control arm) or
      ablation of areas of fragmented electrograms in the right ventricular outflow tract plus
      continued implanted cardioverter defibrillator therapy (intervention arm). A projected 92
      patients in each group will be studied.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom of Ventricular Fibrillation/Tachycardia Recurrences</measure>
    <time_frame>3 year followup</time_frame>
    <description>Survival from ventricular fibrillation of shocked ventricular arrhythmias causing ICD discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom without drug</measure>
    <time_frame>3 years</time_frame>
    <description>Freedom of shocked ventricular arrhythmias without the use of anti-arrhythmic drugs during 3 years of follow-up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>Improvement or decrease of functional status as measured by RAND 36 QOL questionnaires</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Brugada Syndrome</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control arm - continued implanted cardioverter defibrillator therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ablation of areas of fragmented signal in the right ventricular outflow tract plus continued implanted cardioverter defibrillator therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Cross Over Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>these patients were initially assigned to the control arm of the study. When these patients met the primary outcome of the study it is allowed for these patients to be included in the intervention arm and/or to start quinidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter Ablation</intervention_name>
    <description>catheter ablation of fragmented signal in the right ventricular outflow tract</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_label>Single Cross Over Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of Brugada syndrome is based on 2013 HRS/EHRA/APHRS Consensus document
             criteria

          -  The patient received at least 1 appropriate ICD shock within 5 yrs OR ICD implanted
             over 5 years without shock

          -  The patient is legally competent, willing and able to undergo the study and signed the
             informed consent

          -  The patient is willing and able to adhere to the follow-up visit protocol

        Exclusion Criteria:

          -  A patient who does not meet inclusion criteria

          -  A patient who has had a previous epicardial ablation

          -  A patient who is pregnant (which would exclude an ablation procedure)

          -  A patient with a co-morbid condition that possesses undue risk of general anesthesia
             or epicardial ablation

          -  A patient who has a history of radiation therapy on the thorax
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koonlawee Nademanee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Rim Electrophysiology Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Koonlawee Nademanee, MD</last_name>
    <phone>66870708787</phone>
    <email>koonlawee@pacificrimep.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic Medical Center, University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pieter G Postema, MD PhD</last_name>
      <email>p.g.postema@amc.nl</email>
    </contact>
    <investigator>
      <last_name>Pieter G Postema, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur A Wilde, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bhumipol Adulyadej Hospital, Royal Thai Air Force</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gumpanart Veerakul, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gumpanart Veerakul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Koonlawee Nademanee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apichai Khong, MD</last_name>
    </contact>
    <investigator>
      <last_name>Apichai Khong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Rim Electrophysiology Research Institute Data Coordinating Center</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koonlawee Nademanee, MD</last_name>
      <phone>66870708787</phone>
      <email>koonlawee@pacificrimep.com</email>
    </contact>
    <investigator>
      <last_name>Koonlawee Nademanee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tachapong Ngarmukos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanwarang Wongcharoen, MD</last_name>
      <phone>053-289177</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Nademanee K, Raju H, de Noronha SV, Papadakis M, Robinson L, Rothery S, Makita N, Kowase S, Boonmee N, Vitayakritsirikul V, Ratanarapee S, Sharma S, van der Wal AC, Christiansen M, Tan HL, Wilde AA, Nogami A, Sheppard MN, Veerakul G, Behr ER. Fibrosis, Connexin-43, and Conduction Abnormalities in the Brugada Syndrome. J Am Coll Cardiol. 2015 Nov 3;66(18):1976-1986. doi: 10.1016/j.jacc.2015.08.862.</citation>
    <PMID>26516000</PMID>
  </reference>
  <reference>
    <citation>Nademanee K, Veerakul G, Chandanamattha P, Chaothawee L, Ariyachaipanich A, Jirasirirojanakorn K, Likittanasombat K, Bhuripanyo K, Ngarmukos T. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation. 2011 Mar 29;123(12):1270-9. doi: 10.1161/CIRCULATIONAHA.110.972612. Epub 2011 Mar 14.</citation>
    <PMID>21403098</PMID>
  </reference>
  <reference>
    <citation>Ten Sande JN, Coronel R, Conrath CE, Driessen AH, de Groot JR, Tan HL, Nademanee K, Wilde AA, de Bakker JM, van Dessel PF. ST-Segment Elevation and Fractionated Electrograms in Brugada Syndrome Patients Arise From the Same Structurally Abnormal Subepicardial RVOT Area but Have a Different Mechanism. Circ Arrhythm Electrophysiol. 2015 Dec;8(6):1382-92. doi: 10.1161/CIRCEP.115.003366. Epub 2015 Oct 19.</citation>
    <PMID>26480928</PMID>
  </reference>
  <reference>
    <citation>Wilde AA, Nademanee K. Epicardial Substrate Ablation in Brugada Syndrome: Time for a Randomized Trial! Circ Arrhythm Electrophysiol. 2015 Dec;8(6):1306-8. doi: 10.1161/CIRCEP.115.003500.</citation>
    <PMID>26671932</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pacific Rim Electrophysiology Research Institute</investigator_affiliation>
    <investigator_full_name>Koonlawee Nademanee, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ventricular arrhythmias</keyword>
  <keyword>aborted cardiac arrest</keyword>
  <keyword>cardiac death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Brugada Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Medical journals, abstract submissions and results database</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

